Trevi Therapeutics, Inc. Gains 23.97%
Trevi Therapeutics, Inc. (TRVI:NASDAQ) jumped higher at $1.5, representing a gain of 24%. On Fri, Oct 08, 2021, TRVI:NASDAQ hit a New 2-Week Low of $1.2. The stock appeared on our News Catalysts scanner on Thu, Oct 07, 2021 at 05:07 PM in the 'BIOTECH' category. From Fri, Sep 24, 2021, the stock recorded 30.00% Up Days and 36.36% Green Days
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- Protagonist Therapeutics, Inc. (PTGX:NASDAQ), 93.86%
- Adamas Pharmaceuticals, Inc. (ADMS:NASDAQ), 75.05%
- Flexion Therapeutics, Inc. (FLXN:NASDAQ), 58.65%
- PROG (PROG:NASDAQ), 58.52%
- U.S. Well Services, Inc. (USWS:NASDAQ), 25.83%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 23.97%
- Sphere 3D Corp. (ANY:NASDAQ), 23.77%
- GOTU (GOTU:NYSE), 19.35%
- Blue Apron Holdings, Inc. (APRN:NYSE), 17.4%
- Hexindai Inc. (HX:NASDAQ), 15.44%